AstraZeneca: FDA Approves Self-Administered Fasenra Pen
04 October 2019 - 4:43PM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug
Administration approved one of its respiratory medicines as a
self-administered and pre-filled syringe called the Fasenra
pen.
Fasenra, a treatment for severe eosinophilic asthma, can now be
used by patients themselves as an injection administered once every
eight weeks. The pharmaceutical company said that this allows for
more convenient dosing at home.
Fasenra was already approved in the U.S., as well as Europe and
Japan as a drug given by doctors.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
October 04, 2019 02:28 ET (06:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024